Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers on lymphangiogenesis of gastric cancer in a nude mouse model

Renin-angiotensin system (RAS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice

“…In addition, Ager et al [47], using a murine model of liver metastases from colorectal cancer, demonstrated that ACEIs decreased the expression of VEGF and the number of CD34-positive vessels. This decrease in the expression of VEGF with the use of ACEI and ARB was also seen in a murine model of gastric cancer [48]. Taken together, our findings suggest that the blockade of RAS decreases tumor proliferation and metastatic capacity of RCC in this experimental model.…”

Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer

“…Our results showed that the expression of AT1 is associated with vascular density in BC tumors. Accumulating evidence supports the idea that AT1 could play an important role in tumor angiogenesis [30,31,26,32]. However, its association with angiogenesis in breast cancer has been unclear.…”

Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence

“…However, the main effect of ARBs on cancer appears to be mediated through inhibition of the release of pro-angiogenic factors from tumour cells in vitro, observed in vivo as a lower density of blood vessels and reduced tumour volume [21,22]. Tumour size has been shown to be sensitive to ARB treatment in a number of animal models of cancer, including ovarian [23], breast [24], bladder [25], lung [26,27], prostate [28], gastric [29,30], pancreatic [31], sarcoma [27] and glioma [32]. In nearly all animal experiments, ARB administration was associated with a reduced expression of VEGF in tumours regardless of tumour type.…”